Eli Lilly and Company

    Jurisdiction
    United States
    LEI
    FRDRIPF3EKNDJ2CQJL29
    ISIN
    US5324571083 (LLY)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - General

    Scores

    InsiderPie Expert Score
    69 / 100
    Better than peer group:
    62 / 100
    Fair value (Benjamin Graham formula)
    €586.69 23.6% overvalued
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. Read full profile

    Fundamentals

    Net revenue
    €45.43B
    Gross margin
    82.6%
    EBIT
    €19.42B
    EBIT margin
    42.7%
    Net income
    €11.77B
    Net margin
    25.9%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €62.52B +37.6% €23.24B +97.5%
    €72.23B +15.5% €28.12B +21.0%
    €79.78B +10.5% €32.51B +15.6%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    $1.50
    Ex date
    Payment date
    Dividend payout ratio
    36.5%

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Zakrowski Donald A SVP, Finance, & CAO -1K $734.93 -$734.93K
    Montarce Lucas EVP & CFO +715 $691.79 +$494.63K
    Alvarez Ralph N/A +758 $660.25 +$500.47K
    Van Naarden Jacob EVP & Pres., Lilly Oncology +1K $647.36 +$647.36K
    Fyrwald J Erik N/A +1.6K $642.33 +$1.01M

    Congress transactions

    Name Transaction date Value
    Val Hoyle September 12, 2025 $1.00K–$15.00K
    Val Hoyle September 12, 2025 $1.00K–$15.00K
    Julie Johnson September 11, 2025 $1.00K–$15.00K
    David Taylor September 2, 2025 $16.00K–$65.00K
    Jonathan Jackson August 25, 2025 $1.00K–$15.00K

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 96K $79.55M +42K Buy
    Stanley Druckenmiller 95K $78.32M +33K Buy
    Ray Dalio 2.7K $2.27M -82K Sell

    Earnings Calls

    Add to watchlist

    Notifications